Industry Overview

US cell counting market was valued at $662.7 million in 2025 and is projected to reach $1,223.3 million by 2035, growing at a CAGR of 6.4% during the forecast period (2026–2035). The US cell counting market is witnessing steady growth driven by increasing demand for accurate and reliable cell analysis in clinical, research, and industrial laboratories. Expansion of pharmaceutical and biotechnology research activities is contributing to higher adoption of cell counting instruments and consumables. Growing investment in healthcare infrastructure and modernization of diagnostic laboratories is further supporting market development. Advances in instrument design and integration with software solutions are enhancing workflow efficiency and data precision. Rising focus on regulatory compliance and standardized laboratory practices is reinforcing the uptake of advanced cell counting technologies. Additionally, increasing research in regenerative medicine, cell therapy, and immunology is creating sustained demand for high-quality analytical tools.

Market Dynamics

Expansion of Biopharmaceutical and Research Applications

Growth in drug development, cell therapy, and regenerative medicine research is fueling demand for cell counting solutions across the United States. Contract research organizations, academic institutions, and industrial laboratories are expanding analytical capabilities to support complex studies. Leading companies are providing high-throughput, reliable instruments tailored for research-intensive applications. Recent trends include integration of cell counting tools into clinical trial workflows and bioprocess monitoring systems. The focus on precision, reproducibility, and efficiency continues to drive market uptake. As research activities expand, demand for advanced cell counting solutions is expected to remain strong.

Strengthening Healthcare and Diagnostic Infrastructure

Significant improvements in healthcare infrastructure and laboratory modernization initiatives are supporting the growth of cell counting technologies in the US. Hospitals and diagnostic laboratories are investing in upgraded instruments to manage increasing testing volumes and improve patient care. The growing prevalence of chronic and infectious diseases is contributing to higher demand for accurate cell analysis. Recent trends include the deployment of automated systems for routine diagnostics and laboratory workflows. Manufacturers are focusing on solutions that enhance productivity and ensure compliance with regulatory standards. These developments are reinforcing long-term growth and adoption of cell counting technologies across the country.

Market Segmentation

• Based on the product type, the market is segmented instruments and consumables.
• Based on the application, the market is segmented into medical applications, research, and industrial.
• Based on the end-user, the market is segmented into pharmaceuticals & biotechnology companies, research institutes & CRO, and hospitals and diagnostic laboratories.

Cell Counting Instruments Leading Market Growth in the US

Cell counting instruments are the largest sub-segment in the product category, driven by their precision, efficiency, and wide adoption across research, clinical, and industrial laboratories in the United States. Pharmaceutical, biotechnology, and hospital laboratories are increasingly relying on these instruments to ensure reproducibility and rapid analysis. Leading players such as Thermo Fisher Scientific, Beckman Coulter, and Bio-Rad are enhancing offerings with advanced imaging and software-assisted analytics to optimize workflows. Recent trends include integration with laboratory information management systems and connected platforms for streamlined operations. Regulatory compliance and standardized laboratory practices further support adoption. Overall, instruments continue to play a central role in driving market growth across the region.

Pharmaceuticals and Biotechnology Sector Driving Rapid Expansion

The pharmaceuticals and biotechnology end-user segment is the fastest-growing, fueled by rising investments in drug development, cell therapy, and regenerative medicine research. Companies including Agilent Technologies, Merck KGaA, and Nexcelom Bioscience are offering tailored solutions to meet the increasing analytical demands of laboratories in the United States. Expansion of contract research organizations and industrial research facilities is supporting greater adoption of high-throughput cell counting instruments. Recent trends highlight integration of instruments into bioprocess monitoring and clinical trial workflows. Emphasis on accuracy, reproducibility, and regulatory compliance is accelerating adoption. This sub-segment is expected to maintain strong growth throughout the forecast period.

Market Players Outlook

The major companies operating in the US cell counting market include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In December 2025, BD (Becton, Dickinson and Company) announced the global commercial release of new configurations of cell analyzers featuring spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech across scales, needs and budgets to advance discoveries in immunology, cancer immunotherapy and cell biology.

• In March 2025, Sysmex America announced the XQ-320, a 3-part differential automated hematology analyzer designed for rapid and accurate CBC testing with a throughput of up to 70 samples per hour. The compact system provides comprehensive parameters, low sample volume requirements, and minimal maintenance, supporting efficient laboratory operations and timely diagnostic results.

• In August 2024, DeNovix announced new Hepatocytes counting application for the CellDrop Automated Cell Counter. Hepatocytes are widely used in toxicity and drug metabolism testing (ADME / DPMK) and infectious disease research. Using advanced machine-learning techniques, DeNovix scientists developed an automated software algorithm for the CellDrop to deliver simple, reliable hepatocyte counts.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US cell counting market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.